卡瑞利珠单抗不良反应的关联规则分析  

Association rule analysis of adverse reactions of camrelizumab

作　　者：胡晔 龚奇能 谢建翔 张琳琳 尹存林 苏振宇 HU Ye;GONG Qineng;XIE Jianxiang;ZHANG Linlin;YIN Cunlin;SU Zhenyu(Department of Pharmacy,the First People's Hospital of Yancheng,Jiangsu Yancheng 224000,China;Medical Research Center,Nantong First People's Hospital,Jiangsu Nantong 226001,China;Department of Pharmacy,the First Affiliated Hospital of Nanjing Medical University,Nanjing 210029,China)

机构地区：[1]盐城市第一人民医院药学部,江苏盐城224000 [2]南通市第一人民医院临床医学研究中心,江苏南通226001 [3]南京医科大学第一附属医院药学部,南京210029

出　　处：《临床药物治疗杂志》2024年第12期71-75,共5页Clinical Medication Journal

基　　金：南通市卫生健康委员会科研课题(MSZ2023016)。

摘　　要：目的分析卡瑞利珠单抗不良反应的发生特点和规律,为临床安全用药提供依据。方法收集2021年5月至2023年10月南京医科大学第一附属医院和盐城市第一人民医院上报的卡瑞利珠单抗不良反应报告,对患者性别、年龄、原患疾病、不良反应类型、严重程度、转归等进行统计及关联规则分析,挖掘卡瑞利珠单抗发生不良反应的潜在联系。结果卡瑞利珠单抗所致的165份不良反应报告,涉及男118例,女47例,60~69岁患者报告数最多,共57例。收集的报告共涉及不良反应208例次,主要累及器官或系统为消化系统损害45例次(21.63%)、皮肤及附件损害42例次(20.19%)、全身性损害40例次(19.23%)。“严重程度=一般”与“转归=好转”的关联性最强,关联数为142;关联规则显示,前项“年龄=50~59岁”和“性别=女”,后项“不良反应类别=全身性损害”的置信度最高,其置信度和支持度分别为41.48%和8.17%。结论卡瑞利珠单抗易引起消化系统损害,50~59岁的女性患者使用卡瑞利珠单抗更易发生全身性损害。Objective To analyse the characteristics and patterns of ADR associated with camrelizumab,providing a basis for safe utilization of this drug in clinical settings.Methods ADRs of camrelizumab reported by the First Affiliated Hospital of Nanjing Medical University and the First People's Hospital of Yancheng from May 2021 to October 2023 were collected.Patients'information including gender,age,primary disease,ADR type,severity,and outcome were analysed using association rules,to find out the potential associations between ADRs and camrelizumab.Results A total of 165 ADR reports were analyzed,involving 118 male and 47 female patients.Patients aged 60 to 69 years had the highest number of ADR reports with a total of 57 cases.The collected reports involved a total of 208 ADR events,mainly involving 45 cases(21.63%)with digestive system damage,42 cases(20.19%)with skin and accessory damage,and 40 cases(19.23%)with systemic damage to organs or systems.There was a strong correlation between"severity=fair"and"outcome=improved"with an association count of 142.The association rules showed that the confidence level was the highest when"age=50 to 59 years old"and"gender=female"were the antecedents,and"ADR category=systemic damage"was the consequence with a confidence of 41.48%and support of 8.17%.Conclusion Camrelizumab is more likely to cause gastrointestinal damage,female patients aged 50 to 59 years are susceptible to systemic damage when treated with camrelizumab.

关 键 词：卡瑞利珠 不良反应 关联规则 APRIORI算法 

分 类 号：R979.1[医药卫生—药品] R969.3[医药卫生—药学]